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Urinary macromolecular inhibition of crystal adhesion to renal
epithelial cells is impaired in male stone formers
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Urinary macromolecular inhibition of crystal adhesion to renal
epithelial cells is impaired in male stone formers.
Background. Retention of microcrystals that form in tubular
fluid could be a critical event in kidney stone formation. This
study was performed to determine if urinary macromolecules
from stone-forming (SF) individuals have reduced ability to in-
hibit crystal adhesion to renal cells.
Methods. A first morning whole urine (WU) sample was ob-
tained from 24 SF subjects (17 males and 7 females) and 24 age-,
race-, and sex-matched controls (C). An aliquot of urine was
centrifuged and an ultrafiltrate (UF) free of macromolecules
>10 kD and 10× concentrate (Uconc) were prepared.
Results. Supplementing UF with increasing amounts of Uconc
to return the macromolecule concentration to 0.25×, 0.5×, or
1× of baseline progressively decreased crystal binding to cells.
This effect was blunted in the male SF group compared to con-
trols (P < 0.05, SF vs. C, for UF plus 0.25× macromolecules).
No difference was apparent in the female groups. In order to
identify responsible macromolecule(s), calcium oxalate mono-
hydrate (COM) crystals were coated with Uconc and adherent
proteins then released and probed by Western blot. Coated
COM crystals from male controls contained 3.5-fold more
Tamm-Horsfall protein (THP) than SF subjects (P < 0.01).
COM crystal coating with other proteins did not consistently
differ between the groups. COM crystal coating by urinary pro-
thrombin fragment 1 (UPTF1, P < 0.05) and crystal adhesion
inhibitor (CAI) (P = 0.09) correlated with decreased crystal
binding to cells, whereas coating with osteopontin (OPN) cor-
related with increased adhesion tendency (P < 0.05).
Conclusion. Urinary macromolecules >10 kD coat COM
crystals and block their adhesion to renal cells. This capacity
appears to be blunted in male but not female SF individuals.
Multiple urinary proteins may play a role in renal cell-urinary
crystal interactions, and THP appears to be one of the more
important ones.
Key words: MDCKI cells, nephrolithiasis, osteopontin, Tamm-Horsfall
protein, urinary prothrombin fragment 1.
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Urine is often supersaturated so that the formation
of calcium oxalate or calcium phosphate crystals is fa-
vored [1]. However, unless these small crystals grow large
enough to occlude a tubule lumen, aggregate with other
crystals to form a mass large enough to do so, or ad-
here to the tubular epithelium, any intraluminal crys-
tals will be swept out of the nephron in the flowing
fluid within a few minutes [2, 3]. In many calcium ox-
alate stone formers, medullary interstitial calcium phos-
phate deposits appear to precede the formation of larger
stones [4], although the processes that mediate intersti-
tial crystal deposition and evolution into calcium oxalate
stones remain to be defined, and it is conceivable even
these interstitial crystals originate within tubular lumen.
In more marked hyperoxaluric states (e.g., enteric or pri-
mary hyperoxaluria) the pathology differs, and direct ad-
hesion of calcium phosphate or oxalate crystals to renal
epithelial cells, or initial damage of tubular epithelium
by crystals or oxalate ion, may be important [4]. There-
fore, we and others have studied the response of renal
tubular cells to oxalate ions and calcium oxalate and cal-
cium phosphate crystals [5–13], since these events could
trigger a series of events that lead to pathologic renal
calcification.
Adhesion of calcium oxalate crystals to anionic
molecules on the surface of renal epithelial cells is crystal-
face specific [14] and can be blocked by competing
soluble anions in tubular fluid, such as glycosaminogly-
cans, citrate, or glycoproteins [5, 6]. Whole urine itself
can block crystal adhesion to cells [15], and osteopontin
(OPN) [6], nephrocalcin [6], heparan sulfate [6], bikunin
[16], and the recently described crystal adhesion inhibitor
(CAI) [17] have each been found active when tested in
isolation. It has been postulated that crystallization in-
hibitors in the urine of certain stone formers might be
defective, thereby explaining their disease [1]. Studies on
crystallization in the presence of whole urine and frac-
tions isolated from it have lent support to this hypothesis
[18–22]. Therefore, in this study we tested the hypoth-
esis that whole urine from stone-forming individuals is
defective containing macromolecules that coat crystals
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Table 1. Baseline parameters of stone-forming patients
Serum 24-hour urine Urinary supersaturation
#
Age Stones Cr Ca pH Vol Cit Ox Ca Ph UA Mg CaOx Br Ap UA NaUr
Male mean (17) 56.7 2.6 1.2 9.7 6.0 2042 709 0.36 297 1175 836 144 2.04 0.25 3.78 2.45 2.12
Male SD 12.5 1.3 0.1 0.2 0.3 897 300 0.09 114 355 146 46 0.35 1.01 1.65 1.93 0.74
Female mean (7) 54.0 4.9 1.1 9.5 6.0 1680 537 0.35 215 862 610 100 1.80 0.13 3.41 0.78 1.32
Female SD 12.8 7.6 0.2 0.3 0.5 821 266 0.13 96 434 198 37 0.30 1.02 1.75 2.95 1.00
All mean 55.4 3.8 1.1 9.6 6.0 1856 623 0.35 249 997 706 120 1.91 0.24 3.70 1.55 1.71
All SD 13.0 5.7 0.2 0.3 0.4 898 303 0.11 112 436 206 48 0.35 1.04 1.73 2.52 0.95
Abbreviations and units are: serum, creatinine (Cr, mg/dL) and calcium (Ca, mg/dL); urine volume (vol, mL), citrate (Cit, mg), oxalate (Ox, mmol/L), calcium (Ca,
mg), phosphorous (Ph, mg), uric acid (UA, mg), and magnesium (Mg, mg). Urinary supersaturation in D.G. units for calcium oxalate [CaOx, brushite (Br), apatite
(Ap), uric acid (UA), and sodium urate (NaUr)].
less effectively, thereby favoring crystal retention in the
kidney.
METHODS
Patient population
Patients with idiopathic calcium oxalate stone disease,
confirmed (analysis of passed stone) or suspected (ra-
diopaque by radiographic imaging in the absence of
known secondary causes such as gastrointestinal disease
or renal tubular acidosis), were recruited from the Mayo
Stone Clinic (17 men and 7 women). Controls were care-
fully matched for age (within 5 years), sex, and race, and
lacked a history of renal stone disease. Baseline charac-
teristics of the stone formers before treatment are seen
in Table 1. As a group, compared to females, male stone
formers had passed less stones (2.6 vs. 4.9), had a higher
urine volume (2042 vs. 1679 mL), and had a tendency
toward hypercalciuria (297 vs. 215 mg/day) and hyper-
uricosuria (835 vs. 610 mg/day). As expected, given the
criteria of the study, calcium oxalate supersaturation was
increased for both groups (2.04 and 1.80 D.G., respec-
tively, with an upper limit of normal of 1.75 D.G.). For
men and women the mean time since the first stone event
was 14 years and 4 years, and most recent stone event
3 years and 2 years, respectively. Patients were main-
tained on their standard stone treatment protocol for this
trial (thiazide in 7, potassium citrate in 6, and allopurinol
in 2).
Cell culture
Renal epithelial cells of the Madin-Darby Canine
Kidney (MDCK) line, type I, were a generous gift of
Carl Verkoelen (Erasmus University, Rotterdam, The
Netherlands). Cells were grown in Dulbecco-Vogt mod-
ified Eagle’s medium containing 25 mmol/L glucose
(DMEM) at 38◦C in a CO2 incubator as previously
described [13]. To prepare high-density, quiescent cul-
tures, 1 × 106 cells/35-mm plastic plate (9.62 cm2; Nunc,
Naperville, IL, USA) were plated in DMEM containing
10% calf serum and 1.6 lmol/L biotin. Two days later,
when they were confluent, the medium was aspirated and
replaced with fresh medium containing 5% calf serum
and 1.6 lmol/L biotin. The established monolayer was
used for study the next day.
Preparation of human urine samples
A first morning urine sample was obtained from each
subject and control. Whole urine (WU) was centrifuged
(200g × 10 min) to remove cells and debris. Urine os-
molarity was assessed using an osmometer, and 100 mL
of urine was concentrated ∼10-fold using an Amicon
stir cell fitted with a 10-kD cutoff membrane to pro-
duce ultrafiltrate (UF) and 10 mL of 10×-concentrate
(C). The starting volume of urine that was reduced to 10
mL, and hence, the degree of concentration, was normal-
ized between samples (e.g., if the Uosm was 650 mOsm/kg
then 100 mL of urine was concentrated, if 325 mOsm/kg
then 200 mL was employed, and if 1300 mOsm/kg then
50 mL was employed). In this manner, the same quan-
tity of macromolecules, namely those in 100 mL of urine
with a Uosm 650 mOsm/kg, was contained in each final
10 mL concentrate. Total 24-hour urinary osmol excre-
tion is proportionate to body size, and has, therefore,
been used to normalize excretion of urinary analytes be-
tween patients, similar to creatinine [23]. A Uosm of 650
mOsm/kg was chosen as the target in order to mimic a typ-
ical milieu of the distal tubule under conditions of modest
dehydration, while standardizing between patients. The
average first morning Uosm did not differ significantly be-
tween patients and controls as a group. Artificial urine
(AU) was prepared as previously described [24].
Adhesion of crystals to cells
To measure adhesion of crystals to cells, the culture
medium was aspirated and the cells rinsed once with
phosphate-buffered saline (PBS, pH 7.4) and covered
with 2 mL of WU or UF. To the selected plates con-
taining UF, urine concentrate (C) was added (0.2 mL)
to bring the concentration of macromolecules back to
their ambient urinary concentration (1×). [14C] calcium
oxalate monohydrate (COM) crystals were then added
to the cells, achieving a final concentration of 200 lg/mL
(41.6 lg/cm2 of cells). The culture dishes were gently
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agitated for 5 seconds to uniformly distribute the crys-
tals so that they settled to the surface of the cell mono-
layer under the force of gravity. After 2 minutes, buffer
or urine was aspirated and the cells were washed 3 times
with 4 mL of AU, pH 6. The cells and adherent crys-
tals were then liquefied in 1 mL of 10% NaOH for
1 hour and transferred to a scintillation vial containing
4.5 mL of Ecoscint (National Diagnostics, E. Palmetto,
FL, USA), and the amount of radioactivity was measured
[7]. Results were expressed as the percent binding com-
pared to the corresponding UF in order to control for
ionic constituents in the urine sample such as citrate.
Isolation of urinary proteins bound to COM crystals
COM crystals (10 mg) were added to the urinary con-
centrate (C, 2 mL) containing Complete EDTA-free
protease inhibitor cocktail (Roche Applied Science, In-
dianapolis, IN, USA) and incubated overnight at 4◦C
using end-over-end rotation. Crystals were sedimented
by centrifugation (2000g × 5 min) and rinsed 2 times
with ice-cold PBS pH 7.4. To release COM crystal-
bound proteins the crystals were incubated overnight
with 5.0 mL of 0.5 mol/L Tris-EDTA (pH 8.0) via end-
over-end rotation at 4◦C. Released proteins were con-
centrated using a Centricon microconcentrator (10 kD
cutoff). The concentrated COM-bound proteins were
resolved by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) using a 4% to 12% Bis-
Tris gradient gel (Invitrogen, Carlsbad, CA, USA) and
electroblotted onto a polyvinylidene fluoride (PVDF)
membrane (Millipore, Bedford, MA). This membrane
was either stained with Coomassie blue, or probed
with antibodies against Tamm-Horsfall protein (gift of
Y. Nakagawa, University of Chicago), osteopontin (gift of
John Hoyer, University of Pennsylvania), inter a-trypsin
inhibitor (Bikunin, Dako, Denmark), prothrombin frag-
ment 1+2 (gift of Owen Whyte, Mayo Foundation), or
CAI [17].
Reagents
Crystals of COM were prepared from supersaturated
solutions by Y. Nakagawa (University of Chicago) as
reported previously [25]. To prepare radioactive COM
crystals, [14C] oxalic acid (30–60 mCi/mmol; ICN Biomed-
icals, Irvine, CA, USA) was added to a sodium oxalate
solution, producing a specific activity of 105 cpm/mL,
and sufficient calcium chloride was then added to form
a supersaturated solution. The COM crystals that pre-
cipitated had a specific activity of 300 to 450 cpm/lg.
Crystal size and shape were assessed by light and scanning
electron microscopy [11]. COM crystals were cuboidal
to spindle-shaped, and uniformly small, at 1 to 2 lm in
largest diameter. Crystals were sterilized by heating to
180◦C overnight. X-ray crystallography performed by S.
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Fig. 1. Calcium oxalate monohydrate (COM) crystal adhesion to cells
in the presence of whole urine (WU). Confluent cultures were prepared
as described in Methods. Adhesion of crystals to cells in the presence
of whole urine (WU) was greatly reduced compared to an ultrafiltrate
(UF, <10 kD). For males, WU from SF blocked crystal adhesion to cells
less well (35% vs. UF) compared to WU from controls (28% vs. UF)
(∗P = 0.09). For females there was no difference between SF and C.
Values are the mean ± SE for experiments conducted in triplicate.
Deganello (University of Palermo, Italy) demonstrated
that heating did not alter the structure of COM crystals.
All other reagents were purchased from Sigma
Chemical Company, St. Louis, MO, USA, unless other-
wise indicated.
Statistics
Data were compared by Student t test or analysis of
variance (ANOVA) for correlation between crystal coat-
ing by proteins and adhesion to cells using the JMP
software package (SAS Institute, Inc., Cary, NC, USA);
P values less than 0.05 were considered significant. Val-
ues presented are means ± SEM for experiments done in
triplicate.
RESULTS
Whole urine from male stone formers has defective
antiadhesion activity
In control men, WU decreased cellular adhesion of
COM crystals to 29% of that observed in the matching
UF, whereas WU from SF men decreased crystal adhe-
sion to only 35% of UF (P = 0.09 SF vs. C; Fig. 1). WU
from control females inhibited crystal adhesion to cells
to a similar extent as WU from control men (28% of
UF alone), while inhibition of crystal binding by WU
from SF females was slightly lower (26% of UF alone;
Fig. 1). Therefore, the antiadhesion activity of female SF
urine did not differ from controls in this assay. To normal-
ize urinary macromolecular concentration between sub-
jects and construct dilution curves, we then performed the
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Fig. 2. Inhibition of COM crystal adhesion to cells by whole urine proteins from stone formers and controls. Confluent cultures were prepared
as described in Methods. Concentrated macromolecules (C) >10 kD did not block crystal adhesion to cells as well when added to UF in male SF
compared to male C at 0.25× and 0.5× (A), whereas SF and C females did not differ (B). Values are the mean ± SE for experiments conducted in
triplicate for each of 17 male SF and C and 7 female SF and C. ∗P < 0.10, ∗∗P < 0.05 SF vs. C.
crystal binding assays in the presence of either UF or UF
supplemented with Uconc in varying proportions (0.25×
to 1.0×). For each patient, the 1.0× assay point had the
equivalent concentration of macromolecules that would
have been present in urine with an osmolality of 650
mOsm/kg. Supplementing UF with Uconc did not block
crystal adhesion to cells as well in SF men compared to
controls, whereas for females there was no difference be-
tween the 2 groups (Fig. 2). In this reconstitution study a
defect in SF men was only apparent at the higher dilutions
(0.5× and 0.25×), suggesting that the ratio of crystals
to macromolecules must cross a certain critical thresh-
old before the inhibitory activity is lost or impaired. It
is important to note that the amount of Uconc added in
Figure 2 was normalized between patients based on ini-
tial Uosm, whereas WU was not processed or standard-
ized between patients. Therefore, the quantity of macro-
molecules in WU samples may have differed between
subjects, but was standardized for all UF + Uconc sam-
ples. Given these considerations, results with WU and
UF + IX Uconc would not necessarily be expected to be
the same. However, for all experiments (WU and UF +
Uconc) the concentration of all ions and molecules
<10 kD was standardized sample by sample since the
corresponding UF served as a control to which results
were normalized.
Urinary proteins that coat crystals
We next performed experiments to determine which
of the macromolecules in whole urine might be coat-
ing the crystals to block adhesion to cells, if they dif-
fer between patients and controls, and also, if coating
by specific proteins correlated with the variation in crys-
tal binding observed between subjects. COM crystals
(10 mg) were incubated overnight with the 10× Uconc
(2 mL) using end-over-end rotation at 4◦C, the crys-
tals then washed with PBS, and dissolved in 0.5 M
EDTA to release bound proteins, which were resolved
by SDS-PAGE and then electroblotted. A representa-
tive Coomassie stained blot of urinary proteins released
from coated COM crystals of the first 5 stone formers
and matched controls is shown in Figure 3A. The most
prominent crystal binding bands were at 105 kD (cor-
responding to the expected size of THP) and 70 kD
(most likely OPN). These blots were next probed with
antibodies against proteins that have been implicated in
nephrolithiasis (OPN, bikunin, UPTF1, THP, and CAI).
There were no consistent differences in crystal-associated
OPN, bikunin, UPTF1, or CAI between SF and controls
as a group, whereas THP varied dramatically (Fig. 3B).
Although COM crystals bound significant quantities of
THP from the urine of most control subjects, very little
THP from SF urine adhered to the crystals. Since pre-
vious studies have not detected a quantitative decrease
in THP excretion among stone formers as a group [26],
these results strongly point to a functional abnormality
of THP in the stone formers as a group, as has been pre-
viously suggested [27, 28]. Whereas multiple isomers of
OPN have been reported in native urine samples [29], in
these crystal-purified preparations, a single band of OPN
was observed that matched the 70 kD band stained by
Coomassie blue, perhaps due to isomer-specific crystal
adhesion.
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Fig. 3. Coating of COM crystals by urinary proteins. COM crystals were coated with total urinary protein from patients and controls, rinsed,
dissolved, and separated using SDS-PAGE on a 4% to 12% Bis-Tris gradient gel (Nu Page, Invitrogen) as described in Methods (A). Broad-range
molecular weight standards (Bio-Rad, Hercules, CA) appear to the far left (lane M), with sizes indicated. At least 4 prominent protein bands were
detected (A), while Western blots (B) detected bands of the appropriate weight for Tamm-Horsfall glycoprotein (∼100 kD), osteopontin (∼70
kD, lane C), fragments of prothrombin (∼36 kD), and bikunin (∼50 kD). When band intensity was quantified, THP from controls was much more
avidly associated with the crystals than from patients (C). Other proteins did not consistently differ.
Next, we examined the correlation between crystal ad-
hesion and coating of crystals by the individual proteins
for all subjects together. COM crystal coating by UPTF1,
PT, and CAI correlated with inhibition of crystal binding
(P < 0.05), whereas crystal coating with OPN correlated
with increased crystal binding to cells (P < 0.05) (Table 2).
Twenty-four–hour urine chemistries were available for all
SF patients at the time of a recent clinic visit (when they
were recruited for the study), but not controls. There-
fore, we also examined correlations between stone risk
factors and crystal adhesion inhibition as measured by
our assay. At the 0.25× Uconc point, which differentiated
SF and controls, high urinary calcium, oxalate, and uric
acid, low pH and increased supersaturation for calcium
oxalate and uric acid correlated with increased crystal
binding to cells (or decreased inhibitory capacity of the
urine samples) (Table 3). Correlations between urinary
profiles and adhesion inhibition in the SF group were
similar for other Uconc dilutions, as well as the WU assay.
Therefore, the prevailing urinary ionic milieu could influ-
ence macromolecular function. There was no correlation,
however, between drug treatments and crystal adhesion
to cells.
We also examined correlations between the association
of individual proteins and crystal coating behavior. Coat-
ing of crystals with 2 molecules that correlated with de-
creased binding to cells, bikunin and UPTF1, were highly
correlated with each other (Table 4, P < 0.001). Coating
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Table 2. Correlation between crystal binding to cells and protein
coating of crystals
Protein Correlation P value by ANOVA
THP Weak positive 0.35
OPN Positive <0.05
CAI Weak negative 0.45
Bikunin Weak negative 0.35
UPTF1 Negative <0.05
Positive correlations indicate that coating increased binding, whereas a
negative correlation indicates that coating correlated with decreased binding.
Table 3. Correlation between crystal binding to cells in
UF+0.25Uconc and most recent 24-hour urine collection (stone
patients only)
Analyte Correlation P value by ANOVA
Calcium Positive <0.05
Oxalate Positive <0.05
Citrate None 0.45
Uric Acid Positive <0.05
PH Negative <0.05
Supersaturations
CaOx SS Positive 0.09
Br SS None 0.82
Ap SS Negative 0.07
UA SS Negative <0.05
NaUr SS None 0.84
Positive correlation indicate higher 24-hour values correlated with increased
binding, whereas a negative correlation indicates that higher 24-hour values
correlated with decreased binding. Note these analytes were not measured on
the sample assayed for crystal adhesion.
Table 4. Correlation between COM crystal associated urinary
proteins by ANOVA
CAI THP OPN UPTF1 Bik
CAI ×
THP 0.91 (−) ×
OPN 0.28 (−) 0.28 (+) ×
UPTF1 0.27 (−) 0.09 (−) 0.21 (−) ×
Bik 0.06 (−) 0.09 (−) 0.29 (−) < 0.001 (+) ×
Positive correlations indicate that coating increased binding, whereas a
negative correlation indicates that coating correlated with decreased binding.
with THP and OPN tended to be positively correlated
(P = 0.06), whereas coating with THP and bikunin (P =
0.09) or UPTF1 (P = 0.09) tended to be inversely cor-
related (Table 4). These results suggest that THP may
play an indirect role in cell-crystal interactions and that
protein-protein interactions could potentially modulate
cell-crystal interactions.
DISCUSSION
Our results demonstrate that renal cells and urinary
crystals interact in a complex fashion. Proteins in human
urine, including THP, bikunin, UPTF1, OPN, and CAI
can modulate this interaction. The proteins in male stone
former urine appear to be deficient in this regard be-
cause they do not block COM crystal adhesion to cells
to the same extent. The ability of proteins from human
urine to coat crystals and block their adhesion to cells
appears complex, and protein-protein interactions could
indirectly regulate cell-crystal interactions. THP may be
central in this process, and appears to functionally differ
between stone formers and controls.
Although urine is supersaturated with ions of calcium,
oxalate, and phosphate, which favors the formation of
calcium phosphate and calcium oxalate crystals, kidney
stones do not usually form. Many investigators have ex-
plored the factors that might explain this observation, and
confirmed the presence of molecules in urine that oppose
crystallization. It has been postulated that crystallization
inhibitors in the urine of certain stone formers might be
defective, thereby explaining their disease [1]. Many of
the molecules in urine that inhibit crystallization appear
to be anionic glycoproteins [30]. An example is uropontin
(Mr 50–72 kD), an aspartic acid-rich protein identical to
bone osteopontin [31, 32], and a potent inhibitor of COM
crystal growth [31–33]. THP, the most abundant protein in
normal human urine, does not block COM crystal growth
[34], but does effectively prevent COM crystal aggrega-
tion [35]. Although functionally abnormal THP has been
detected in the urine of stone-forming individuals [27, 36–
38], the role of THP during renal stone formation remains
unclear. The number of proteins isolated from human
urine that inhibit calcium oxalate crystallization contin-
ues to grow and now includes 2 molecules that could be
derived from plasma: human urinary prothrombin frag-
ment 1 (UPTF1) [39] (UPTF1, Mr 31 kD, previously
identified as crystal matrix protein [40]), and bikunin
(Mr 35 kD), the light chain of inter-alpha trypsin inhibitor
[41]. Many of the anionic constituents of human urine that
alter COM crystal growth also block adhesion of crystals
to renal cells, including osteopontin [6] and bikunin [16].
The effect of UPTF1 on adhesion of COM crystals to
renal cells has not yet been reported. We recently identi-
fied a protein present in human urine and renal epithelial
cell conditioned medium that can block crystal adhesion
to cells, named CAI [42]. The effect of CAI on crystal
growth and aggregation is currently unknown. The cur-
rent study suggests that whole urinary proteins acting in
concert can block COM crystal adhesion to cells, and this
property of WU appears to be abnormal in the urine of
male stone formers as a group.
Results with THP were of particular interest. Although
its function remains enigmatic, the kidney produces co-
pious amounts of THP, with 50 to 100 mg excreted daily
in the urine [43]. The protein is produced by cells of
the thick ascending limb [43], and is a GPI-anchored
membrane glycoprotein that is then cleaved by a specific
protease yielding the urinary form [44]. Increasing the
concentration of sodium, chloride, calcium, and hydro-
gen ions causes the protein to self-aggregate and form a
gel, which is thought to be the mechanism of urinary cast
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Fig. 4. Potential cell-crystal interactions. Calcium phosphate (CaP) or calcium oxalate crystals within luminal fluid can interact with urinary proteins,
perhaps alone or complexed together, which modulates (positively or negatively) their adhesion to renal cells (A). THP appears to be central in
these interactions, and may be functionally abnormal in stone formers. Once adherent, crystals can be internalized within vesicles (B). From here,
crystals could be transcytosed to the interstitium (C), or dissolve, releasing Ca, Ox, and P (D). These ions, or other secondary signals, could trigger
gene transcription, cell proliferation, or interstitial fibrosis [54].
formation [45]. Although THP does not appear to be in-
corporated into the matrix of crystals formed in urine
[46], it can tightly associate with the surface of crystals,
perhaps due to its polyanionic nature, and potently in-
hibits aggregation. In doing so, the glycoprotein may al-
ter exposure of the crystal to other anions in urine [47].
Perhaps relevant to the present results, 2 recent studies
suggest that knockout mice without THP are more sus-
ceptible to urinary tract infection with type 1-fimbriated
Escherichia coli [48, 49]. Furthermore, very recently Mo
et al observed that 4 of 25 THP knockout mice exhibited
spontaneous renal crystal deposition, whereas none of the
control littermates showed any crystal deposition. When
these knockout mice were stressed with ethylene glycol
and vitamin D, renal crystal deposition was more frequent
and severe in the THP knockout mice when compared to
the control mice [50].
Of note, coating of crystals with THP and the potent
crystallization inhibitors UPTF1 and bikunin tended to
be inversely correlated, supporting a key role for THP as
a mediator of crystal-protein interactions and, hence, of
cell-crystal interactions (Fig. 4). For example, THP might
block access of crystals to other proteins such as OPN
which, in this study, was correlated with increased crystal
adhesion to cells. Given its heterogeneous glycosylation
pattern, which appears to be genetically determined [51],
our studies support the hypothesis that this glycosylation
difference changes the way THP interacts with crystal sur-
faces, and hence, the way the crystal interacts with a cell.
Further, when present as a single protein in solution, the
properties of each protein could well differ. Therefore,
in future studies it will be of extreme interest to study
urinary macromolecules alone and in mixtures.
The conditions we used to coat the COM crystals dif-
fered from several studies in the literature. Ryall et al
have found that when calcium oxalate crystals are pre-
cipitated in human urine, UPTF1 is the major protein in-
corporated into the crystal matrix [46]. Our studies used
preformed crystals so that no protein became part of the
inner crystalline structure. The properties of proteins that
coat the surface may well differ from those that incor-
porate into the matrix. However, proteins that coat the
crystals are likely most important for regulating initial
cell-crystal interactions, such as adhesion to cells. Fur-
ther, the proteins that we extracted from coated crystals
should correspond best with those that coated crystals
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during our in vitro binding experiments. It has also been
reported that the ambient pH may affect coating of COM
crystals by proteins and the subsequent binding to cells
[52]. In our studies, we correlated crystal binding to the
cells in the presence of whole urine with the proteins that
coated COM crystals in that same urine at the same pre-
vailing urinary pH. Therefore, pH was controlled sample
by sample. In the future, it will be of interest to compare
the effects of pH on coating COM crystals by individ-
ual urinary proteins, and perhaps mixtures of proteins.
The correlations between urinary risk factors and crystal
adhesion to cells in our assay are also of interest. Since
the urinary ionic composition was controlled sample by
sample via the experimental design, with each urinary
ultrafiltrate serving as a control for the corresponding
urine sample, the results suggest that the ionic milieu may
importantly influence macromolecular function and the
ability to coat crystals. For example, hypercalciuria may
not only favor growth of crystals, but also their adhesion
to cells. We previously observed that increasing calcium
concentrations promoted crystal adhesion to cells in the
absence of proteins [53].
CONCLUSION
Our results demonstrate that the urinary macro-
molecules >10 kD can coat COM crystals and block
their adhesion to renal cells. This COM crystal adhe-
sion inhibitory activity appears to be blunted in male
stone-forming individuals, but not in the small number
of female stone formers studied. THP, OPN bikunin,
UPTF1, and CAI may all play a role in renal cell-urinary
crystal interactions via complex interactions. THP in
particular appears to play an important role either by
directly regulating cell-crystal interaction or by regulat-
ing protein-protein interaction. In the future it will be
of interest to define these important protein-protein in-
teractions, and their effect on cell-crystal interactions
(adhesion, internalization, and cellular processing).
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